BioCryst Pharmaceuticals, Inc. BCRX

Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. […]

Beneath the headline-driven sentiment of biotech investing lies the true engine of value creation: portfolio durability, capital efficiency, and sustainable revenue compounding. Founded on the promise of structure-based drug design, BioCryst Pharmaceuticals (NASDAQ:BCRX) has evolved from a speculative research shop into a commercial-stage rare disease specialist. The company’s core operational drivers now center on maximizing […]

BCRX is flashing a historically bullish signal

On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug “Orladeyo,” is looking to acquire more rare disease treatments, according to CEO Charlie Gayer. Gayer, who took the role in January, said the company expects to keep growing profits every year and does […]

BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCryst Pharmaceuticals, with the share price falling 18.47% over the past week and 16.63% over the past month, yet still showing an 8.27% year to date share price return and a 5.45% one year total shareholder return. This suggests that short term momentum is...

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index shedding 0.2% and the

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.

BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema tr

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients.

NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo® (berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.1 “The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty

The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET. The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biote

CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.